Aurobindo Pharma has informed that the company received a warning letter from Securities Exchange Board of India (SEBI) on June 24, 2022, a copy of which is enclosed. The letter is in regards to certain disclosures made by the Company on the ongoing USFDA audit of Company's Unit-1 and observations made by the USFDA between the period 2019-2022. The SEBI warning letter observes that the Company had disclosed very limited and restricted information and that the Company did not disclose the detailed reasons and also did not consider the observations of USFDA as serious. The Company is advised to ensure compliance with all applicable provisions of SEBI Regulations and to place this warning letter before its Board of Directors in ensuing Board Meeting.
The above information is a part of company’s filings submitted to BSE.
